福森药业股东将股票存入银河证券香港 存仓市值3806.88万港元

Group 1 - The core point of the article highlights that Fosun Pharma (01652) has deposited shares worth HKD 38.0688 million into Galaxy Securities Hong Kong, representing 5% of the total shareholding [1] - Fosun Pharma announced that its research and development product, "Metformin and Empagliflozin Tablets (I)", has received approval from the National Medical Products Administration of China for use in treating type 2 diabetes in adults [1] - The approved medication is intended to be used in conjunction with dietary control and exercise for patients already receiving treatment with Empagliflozin and Metformin hydrochloride to improve blood sugar control [1]